New bypass device could spare rectal cancer patients from stoma surgery
NCT ID NCT04184973
First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This trial tests a temporary bypass device called CG-100 in 250 rectal cancer patients undergoing surgery. The device is placed inside the bowel to protect the surgical connection, potentially reducing the need for a temporary stoma. Researchers will compare stoma rates and complications between patients who get the device and those who receive standard stoma surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CG-100 intraluminal bypass device
- What this could lead to
- If it works, this device could help many rectal cancer patients avoid a temporary stoma and its associated complications after surgery.
- What could go wrong
- This is a mid-stage trial with 250 participants, so results may not apply to all patients. The device may not reduce stoma rates as hoped, and there are risks of device-related complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2020
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. The patient is willing to comply with protocol-specified follow-up evaluations 2. Patient 22-65 years of age at screening, or patient 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed. 3. Patient is diagnosed with colorectal cancer 4. Patient is scheduled for elective either open, laparoscopic or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis, maximally 10 cm from the anal verge 5. Patients who are scheduled to receive a protective stoma under routine clinical practice during their primary planned operation. 6. Patient is scheduled to undergo mechanical bowel preparation 7. The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB). Exclusion Criteria: 1. Patient has local or systemic infection at the time of intervention (e.g., peritonitis) 2. Major surgical or interventional procedures within 45 days prior to this study or planned surgical or interventional procedures within 6 months of entry into this study (not including, placement of port for chemotherapy or ureter stent insertion). 3. Patients with ASA classification \> 3 4. Albumin \< 30 g/liter 5. Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease 6. Patients has a diagnosis of coagulopathy, thrombocytopenia, immune suppression 7. BMI ≥ 40 8. Patient is going through another surgical procedure (other than ileostomy, adhesiolysis) during the surgery. 9. The patient is currently participating in another investigational drug or device study unless pre-approved by the sponsor. 10. Patient has been taking regular systemic/ steroid medication in the last 6 months. 11. Patients is taking antimetabolites or antiplatelet agents. 12. Patient has preexisting sphincter problems 13. Patient has evidence of extensive local disease in the pelvis or has undergone a prior pelvic anastomosis. 14. Patients with massive diverticulosis at the sigmoid/descending colon (viewed on preoperative CT) 15. Any condition or abnormality which in the opinion of the investigator may jeopardize the patient's safe participation or the quality of the data 16. Pregnant or nursing female patients. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites in 5 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Asklepios
RECRUITINGHamburg, Germany
-
CHUV
RECRUITINGLausanne, Switzerland
-
Colorado University Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
-
Henry Ford Health System
RECRUITINGDetroit, Michigan, 48202, United States
-
Humanitas Research Hospital
RECRUITINGMilan, Lombardy, 20089, Italy
-
Kaiser Permanente San Diego medical Center
RECRUITINGSan Diego, California, 92123, United States
-
Lifespan & Brown Surgical Associates
ACTIVE_NOT_RECRUITINGProvidence, Rhode Island, 02906, United States
-
Soroka University Medical Center
RECRUITINGBeersheba, 85025, Israel
-
University of California Irvine
ACTIVE_NOT_RECRUITINGIrvine, California, 92868, United States
-
University of Utah Health
ACTIVE_NOT_RECRUITINGSalt Lake City, Utah, 84132, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A bag that holds the small intestine could change colon surgery
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can two immunotherapy drugs help rectal cancer patients skip pelvic radiation?
- Can digital surveys capture the full toll of rectal cancer treatment?
- Can a targeted drug conjugate outsmart advanced colorectal cancer?
- Can a platform trial match the right drug combo to each tumor?